Search

Displaying results 541 - 550 of 4626 in total
  1. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases. … A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818].

  2. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    By reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … It was discovered by phage display technology [A32017].

  3. Drug

    Leucovorin

    go.drugbank.com/drugs/DB00650
    ApprovedInvestigational

    [A275451] It is primarily indicated for "leucovorin rescue" to diminish the hematologic and mucosal toxicity of high-dose methotrexate therapy in osteosarcoma and to treat inadvertent overdoses of folic … [L56092, A257419] Unlike folic acid, leucovorin does not require the enzyme dihydrofolate reductase (DHFR) for activation, allowing it to function even when DHFR is inhibited by drugs like methotrexate

  4. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.

  5. Drug

    Cefroxadine

    go.drugbank.com/drugs/DB11367
    ApprovedWithdrawn

    It was used in Italy but has since been withdrawn.

  6. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    [L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]

  7. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug

  8. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    [L23524] In November 2021, the same indication was approved by the EMA. … Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA.

  9. Drug

    Rosuvastatin

    go.drugbank.com/drugs/DB01098
    ApprovedInvestigational

    as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by … [A181523] This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4,

  10. Drug

    Brinzolamide

    go.drugbank.com/drugs/DB01194
    Approved

    [A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate.